Search - tctmd.com

Displaying 661 - 680 of 879

Sort: Relevancy | Date

Presentation TCT 2013

FREEDOM: A Prospective, Randomized Trial of First Generation Drug-Eluting Stents vs. CABG in Insulin- and Noninsulin-Treated Diabetic Patients

Presenter: George Dangas

October 31, 2013

Presentation TCT 2013

Update on Device Therapy for STEMI: Stents and Thrombectomy/Embolic Protection

Presenter: Praveen Chandra

October 31, 2013

Presentation TCT 2013

Indigenous Stents: New Technologies and Clinical Data

Presenter: Sreenivas Kumar

October 31, 2013

Presentation TCT 2013

DUTCH PEERS (TWENTE II): A Prospective, Randomized, "All-Comers" Trial of Third-Generation Zotarolimus-Eluting Stents vs. Everolimus-Eluting Coronary Stents

Presenter: Clemens von Birgelen

October 31, 2013

Presentation TCT 2013

Drug-Eluting Balloons vs. Everolimus-Eluting Stents for Treatment of In-Stent Restenosis

Presenter: J?rg Schr?der

October 31, 2013

News Conference News TCT 2013

DUTCH PEERS: Third-Generation Stents Equivalent, Effective

October 31, 2013

Presentation TCT 2013

Case 4 : A Complex Bifurcation with Planned 2 Stents

Presenter: Alaide Chieffo

October 30, 2013

Presentation TCT 2013

Case #1: One or Two Stents? Long-term Results from Nordic Baltic I Changed My Strategy!

Presenter: Michael Maeng

October 30, 2013

Presentation TCT 2013

Case #11: In the Future Bifurcation Stents Will Disappear!

Presenter: Evald Christiansen

October 30, 2013

Presentation TCT 2013

RIBS V: A Prospective, Randomized Trial of Paclitaxel Coated Balloon Angioplasty vs. Everolimus-Eluting Stents in Bare Metal In-Stent Restenosis

Presenter: Fernando Alfonso

October 30, 2013

Presentation TCT 2013

New Stents

Presenter: Sotirios Tsimikas

October 30, 2013

News Conference News TCT 2013

VA Medical Centers’ CART Program Improves Patient Care, Longitudinal Research

October 30, 2013

News Conference News TCT 2013

Two Studies Examine Two-Stent Strategy vs. Provisional Stenting in Coronary Bifurcation Lesions

October 30, 2013

News Conference News TCT 2013

SORT-OUT VI: Permanent Polymer ZES Noninferior to Biodegradable BES in All-Comers Study

October 30, 2013

News Conference News TCT 2013

SMART-CASE: Conservative Revascularization Noninferior to Aggressive Approach

October 30, 2013

News Conference News TCT 2013

PROTECT: ZES Lowers Thrombosis Rates Over SES at 4 Years

October 30, 2013

News Conference News TCT 2013

PCI vs. CABG a Close Call in Some Complex Patients

October 30, 2013

News Conference News TCT 2013

Memories of TCT 1988 and Beyond: Julio C. Palmaz, MD

October 30, 2013

News Conference News TCT 2013

Innovation in Intervention: Perspectives from Industry

October 30, 2013

Presentation TCT 2013

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

Presenter: Byoung Kwon Lee

October 29, 2013

Advertisement

FREEDOM: A Prospective, Randomized Trial of First Generation Drug-Eluting Stents vs. CABG in Insulin- and Noninsulin-Treated Diabetic Patients

Update on Device Therapy for STEMI: Stents and Thrombectomy/Embolic Protection

Indigenous Stents: New Technologies and Clinical Data

DUTCH PEERS (TWENTE II): A Prospective, Randomized, "All-Comers" Trial of Third-Generation Zotarolimus-Eluting Stents vs. Everolimus-Eluting Coronary Stents

Drug-Eluting Balloons vs. Everolimus-Eluting Stents for Treatment of In-Stent Restenosis

DUTCH PEERS: Third-Generation Stents Equivalent, Effective

Case 4 : A Complex Bifurcation with Planned 2 Stents

Case #1: One or Two Stents? Long-term Results from Nordic Baltic I Changed My Strategy!

Case #11: In the Future Bifurcation Stents Will Disappear!

RIBS V: A Prospective, Randomized Trial of Paclitaxel Coated Balloon Angioplasty vs. Everolimus-Eluting Stents in Bare Metal In-Stent Restenosis

New Stents

VA Medical Centers’ CART Program Improves Patient Care, Longitudinal Research

Two Studies Examine Two-Stent Strategy vs. Provisional Stenting in Coronary Bifurcation Lesions

SORT-OUT VI: Permanent Polymer ZES Noninferior to Biodegradable BES in All-Comers Study

SMART-CASE: Conservative Revascularization Noninferior to Aggressive Approach

PROTECT: ZES Lowers Thrombosis Rates Over SES at 4 Years

PCI vs. CABG a Close Call in Some Complex Patients

Memories of TCT 1988 and Beyond: Julio C. Palmaz, MD

Innovation in Intervention: Perspectives from Industry

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content